Upcoming FDA Meeting to be Type C Meeting THE WOODLANDS,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Upcoming FDA Meeting to be Type C Meeting

THE WOODLANDS, Texas, Oct. 16, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq: RPRX ) today reported that its upcoming meeting with the FDA in the first half of November will be a Type C guidance meeting rather than a Type B Pre-NDA meeting. The Company received a communication from the FDA today indicating that based on its preliminary review of the Company's briefing document, there was not sufficient clinical information provided for the meeting to be a Type B Pre-NDA meeting.

While the Company does not know why the FDA believes the clinical information to not be sufficient, the Company notes that synopses for the one year DEXA safety study and the Drug-Drug Interaction Study, which it believes may be significant to the FDA's review, were not available at the time the briefing document was submitted to the FDA.

The FDA indicated that it would like to proceed with the meeting as a Type C Guidance meeting, and that it will provide preliminary comments to the Company's questions prior to the meeting.

About Repros Therapeutics Inc.®

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Forward-Looking Statements

Any statements made by the Company that are not historical facts contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertainties and other factors that could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as "may," "will," "expect," "anticipate," "continue," "estimate," "project," "intend," "believe," "plan," "seek," "could," "can," "should" or similar expressions. These statements are based on assumptions that the Company has made in light of the Company's experience in the industry, as well as the Company's perceptions of historical trends, current conditions, expected future developments and other factors the Company believes are appropriate in these circumstances. Forward-looking statements include, but are not limited to, those relating to planned clinical studies and the timing and nature of the results thereof, the impact of the studies on the Androxal® label and the commercial potential of Androxal® and the timing of the Company's expected filing of an NDA for Androxal®. Such statements are based on current expectations that involve a number of known and unknown risks, uncertainties and other factors that may cause actual events to be materially different from those expressed or implied by such forward-looking statements, including the ability to have success in the clinical development of the Company's technologies, the reliability of interim results to predict final study outcomes, the ability to protect the Company's intellectual property rights and such other risks as are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov . Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company's website at http://www.reprosrx.com .

Investor Relations: Thomas Hoffmann The Trout Group (646) 378-2931

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 68

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 48

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 164

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
Utility Global’s India Steel Move Needs Hard Numbers

Updated Category News Views 38

Steel decarbonization announcements can sound enormous before a single bolt gets tightened. Utility Global says it plans to deploy its first industrial H2Gen project in India with Tata Steel, and that is plainly worth watching. Tata Steel is a serious industrial name, India is a consequential steel market, and any technology that can credibly lower emissions from heavy...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 37

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 71

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading

Top 5 Most Recently Viewed Articles

MPE Partners Invests in SKB Cases to Enhance Growth Potential

Updated Category News Views 369

MPE Partners Makes Strategic Investment in SKB Cases MPE Partners, also known as Morgenthaler Private Equity, has announced an exciting investment in SKB Cases, a prominent manufacturer known for its specialty protective cases. With a robust customer base exceeding 2,000 clients across military, industrial, music, and pro AV sectors, this strategic move is set to...

Continue Reading
Aspire Expands into Europe with EU EMI License and Hub Establishment

Updated Category News Views 186

Aspire Expands into Europe with EU EMI License Aspire, a leading global fintech firm based in Singapore, recently announced a significant breakthrough by acquiring its Electronic Money Institution (EMI) license. This important approval lays the groundwork for its operations in the Netherlands, marking the company's formal entry into the European Union. Milestone for...

Continue Reading
GOTS Combats Greenwashing with Consumer Education Campaign

Updated Category News Views 128

GOTS Takes Action Against Greenwashing The Global Organic Textile Standard (GOTS) is excited to announce the return of its #BehindTheSeams campaign, which aims to raise awareness about the sustainable features of GOTS-certified products. This year's campaign will run throughout September, expanding its efforts to educate consumers about the sustainable practices behind...

Continue Reading
Advancements in Cancer Treatment: Insights from Indaptus Therapeutics

Updated Category News Views 123

Exciting Clinical Developments by Indaptus Therapeutics Indaptus Therapeutics, Inc. (Nasdaq: INDP) is making significant strides in the realm of cancer therapy, focusing on innovative treatments for complex conditions such as urothelial cancer. Their ongoing clinical trial, labeled INDP-D101, has revealed promising results regarding their Decoy20 monotherapy. Recently, a...

Continue Reading
Dr. Réjean Boivin Appointed as Editor-in-Chief of Journal

Updated Category News Views 474

Dr. Réjean Boivin Takes the Helm at Review of Scientific Instruments AIP Publishing is excited to welcome Dr. Réjean Boivin as the new editor-in-chief for Review of Scientific Instruments. Boivin, who previously directed the Center of Excellence for Advanced Diagnostics at General Atomics, is a well-respected figure in the field, having held various roles such as...

Continue Reading